#ELUCIDATE SOFTWARE SOFTWARE#
#ELUCIDATE SOFTWARE PROFESSIONAL#

#ELUCIDATE SOFTWARE PROFESSIONAL#

The results from TumorScope™ are intended to be used in conjunction with the oncologist’s professional judgment, patient’s clinical history, symptoms, and other diagnostic tests.

A tumor viewer is also made available for orientation purposes, and enables visualization of tumor response by both patient and clinician.These metrics are used to support qualified physicians in evaluating the right regimen for a specific patient.MRIs, mammograms, histology, and genetic tests are used in the model to generate predictive metrics such as expected tumor volume, change in tumor volume %, PCR Score, and drug uptake score.It provides quantitative and qualitative analysis of a patient’s potential response to therapy, generated with a 3D computational model incorporating previously acquired diagnostic data. SimBioSys TumorScope™ currently aids the identification of the safest and most efficacious drug regimens for breast cancer patients. In this way, precision oncology approaches can be applied to increase life-expectancy for racial minorities with breast cancer. By characterizing racial-specific tumor intrinsic and extrinsic biological factors and their potential interactions, strategies may emerge to personalize clinical management based on racial differences. Results: AA patients have tumors that display higher growth rates, characteristically have higher adipose tissue around the tumor, higher spatial variation in drug secretion, lower spatial variation in blood flow/ and increased tumor stiffness.Ĭonclusion: Using a transdisciplinary approach, our results show that metabolic and structural tumor features are associated with the disproportionately poor survival rates observed in AA breast cancer patients.

#ELUCIDATE SOFTWARE SOFTWARE#

Methods: Imaging and transcriptomic data from over 500 patients were integrated within the SimBioSys TumoScope biophysical modeling software to understand racial differences in tumor biology and coordinated tumor behavior. As a result, we have developed a platform that combines patient-specific imaging and multi-omics data to elucidate how biological differences integrate to promote racial disparities in tumor behavior and patient outcome.

Tumor intrinsic and extrinsic factors that promote racial differences in breast cancer development and patient outcome are not fully understood and strategies to address this are scarce. Research into these racial disparities has primarily focused on socioeconomic determinants, with some studies exploring potential molecular determinants and limited biological differences found between AA and Caucasian patient tumors. In particular, African American (AA) patients have higher mortality rates than other racial groups. Background: Racial disparities in breast cancer incidence and clinical outcome have been well characterized.

Elucidate software